Fig. 3: Best RECIST response and time on study in Module 2A. | Nature Communications

Fig. 3: Best RECIST response and time on study in Module 2A.

From: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Fig. 3

A Best response. Each bar represents the best percentage change from baseline for an individual patient. N = 25 (Note: only participants with at least one post-baseline value are included in this figure). B Time on study. Time on study for each patient (presence of liver metastases and mutation status for each patient also indicated). N = 25. CBR24 clinical benefit rate at 24 weeks, mt mutation detected.

Back to article page